Table 2.
5-year survival probability of patients with tumors by tumor type (PHEO vs. PGL) and tumor size based on the presence of synchronous metastasis
| Without synchronous metastases (n = 78) | Synchronous metastases (n = 28) | 5-year/overall survival p-value | |
|---|---|---|---|
|
All tumors by type | |||
| PGL (n = 89) |
97.9% (n = 66) |
73.2% (n = 23) |
0.0002/0.001 |
| PHEO (n = 17) |
88.9% (n = 12) |
80.0% (n = 5) |
0.56/0.94 |
| 5-year/overall survival p-value |
0.19/0.012 |
0.79/0.89 |
--- |
|
All tumors by size | |||
| <5.5 cm (n = 44) |
95.2% (n = 37) |
100% (n = 7) |
0.63/0.41 |
| > = 5.5 cm (n = 62) |
97.1% (n = 41) |
65.8% (n = 21) |
0.0003/0.0028 |
| 5-year/overall survival p-value |
0.71/0.18 |
0.09/0.021 |
--- |
|
PGLs by size | |||
| <5.5 cm (n = 41) |
94.7% (n = 34) |
100% (n = 7) |
0.61/0.40 |
| > = 5.5 cm (n = 48) |
100% (n = 32) |
60.9% (n = 16) |
0.0001/0.0002 |
| 5-year/overall survival p-value |
0.22/0.57 |
0.068/0.014 |
--- |
|
PHEOs by size | |||
| <5.5 cm (n = 3) |
100% (n = 3) |
N/A |
N/A |
| > = 5.5 cm (n = 14) |
85.7% (n = 9) |
80.0% (n = 5) |
0.68/0.86 |
| 5-year/overall survival p-value | 0.59/0.38 | N/A | --- |